Trial Profile
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Germ cell cancer; Testicular cancer
- Focus Therapeutic Use
- Acronyms CabaReGeCe
- 01 Feb 2024 Status changed from recruiting to discontinued (due to insufficient recruitment).
- 18 Jul 2022 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 18 Jul 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.